August 17, 2004Circulation
Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome
Why the study?
Does clopidogrel added to aspirin reduce the composite of cardiovascular death, MI, or stroke in patients with Non-ST-Elevation Acute Coronary Syndrome?
Population
12,562 patients with Non-ST-Elevation Acute Coronary Syndrome (unstable angina)
Comparison
Clopidogrel in addition to aspirin vs Placebo in addition to aspirin
Design
RCT, randomized
Authors
Discussion
Loading...
Member takes
Implication
Supports clopidogrel addition to aspirin across all NSTE-ACS strategies; confirms consistent benefit irrespective of PCI, CABG, or medical therapy.
Structured PICO
Does clopidogrel added to aspirin reduce the composite of cardiovascular death, MI, or stroke in patients with Non-ST-Elevation Acute Coronary Syndrome?
P
Population
12,562 patients with Non-ST-Elevation Acute Coronary Syndrome (unstable angina)
I
Intervention
Clopidogrel in addition to aspirin
C
Comparator
Placebo in addition to aspirin
O
Outcome
Composite of cardiovascular (CV) death, myocardial infarction (MI), or strokecomposite
The benefits of starting clopidogrel on admission in addition to aspirin outweigh the bleeding risks in patients with NSTE-ACS, including those who subsequently undergo surgical or percutaneous revascularization.
Cite This Study
Fox et al. (2004) studied this question.